2021 Generics and Biosimilars Outlook
This article first appeared in Chain Drug Review on January 5, 2021 as Pharmacy Outlook: Dan Leonard.
The CREATES Act Passed! — #PassedCREATES
The CREATES Act passed! Patients will now score greater savings and increased access to #generic and #biosimilar medicines. Join us in thanking all who have advocated for its passage. Learn more: http://bit.ly/PassedCREATESRelease
AAM Statement on House Energy & Commerce Passage of the CREATES Act
WASHINGTON, DC (April 3, 2019) – The Association for Accessible Medicines welcomes today’s unanimous 51-0 passage of the CREATES Act by the House Energy and Commerce Committee.
AAM Statement: 2019 Energy and Commerce Health Subcommittee Markup
WASHINGTON, DC (March 27, 2019) – The generic and biosimilar industry greatly appreciates the efforts of the Energy and Commerce Health Subcommittee to pass the CREATES Act and advance this bipartisan market-based solution to end abuse of FDA’s safety programs. Today’s markup, unfortunately, represents one step forward and two steps back for patients who want competition to lower drug prices.
Statement from the Association for Accessible Medicines on the Introduction of the CREATES Act
WASHINGTON, DC (February 8, 2019) — The high price of prescription drugs is the number one domestic policy issue in this country, and the CREATES Act is a bipartisan solution that will address some of the anticompetitive tactics that drive prices ever-higher. CREATES has been studied, debated and voted out of committee. Now it is time for the full Congress to take up and pass this critical legislation.
$13.4 Billion a Year! Brand “Shenanigans” Are Costing Patients More Than Ever
When a brand-name prescription drug’s market exclusivity (its monopoly) and patents expire, generic and biosimilar medicines become available, the savings begin and patients win. That’s how the system is supposed to work. However, brand-name pharmaceutical companies have increasingly abused FDA’s safety programs (Risk Evaluation and Mitigation Strategies, or REMS) and other manufacturer-imposed restricted distribution of samples to delay competition and impede patient access to more affordable prescription drugs.
Lost Prescription Drug Savings in the U.S.
Patients are paying too much! A recent study shows that $13 billion a year in prescription drug savings are lost to brand prescription abuses.
When a brand-name prescription drug’s market exclusivity (its monopoly) and patents expire, generic and biosimilar medicines become available, the savings begin and patients win. That’s how the system is supposed to work.
New Study Finds Patients, Government and Insurance Lose $13.4B in Potential Savings By Brand Drug Companies’ Abuses
Study Finds Costs of Brand Abuses Have Exploded in 4 Years, Harming Patient Access to Affordable Generic and Biosimilar Medicines
Highlights from Craig Burton on the Newly Released 2018 Generic Drug Access & Savings Report
AAM's VP Policy Craig Burton shares the release of the 2018 Generic Drug Access & Savings in the U.S. report, which focused this year on savings from patient utilization of generic drugs. The report highlights 3 important findings:
AAM Provides Comments in Response to Administration’s Blueprint on Drug Pricing
Generic and Biosimilars Competition Drives Lower Prices and Reduced Out-of-Pocket Costs for Patients